---
schema_version: "secwatch.filing_event.v1"
accession: "0001077183-23-000039"
form_type: "8-K"
ticker: "NEO"
cik: "0001077183"
company_name: "NEOGENOMICS INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T12:08:50.222294+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance

## Summary
- Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.
- Net loss improved to $31M from $49M; Adjusted EBITDA loss narrowed to $7M from $19M.
- FY2023 revenue guidance raised to $555-$565M from $545-$555M; Adj. EBITDA loss guidance improved to $(22)-$(18)M.
- Cash and marketable securities $418M; adjusted gross profit margin 43.5%.
- Clinical test volume +7% YoY; revenue per test +8% to $402.

## SEC filing metadata
- accession: 0001077183-23-000039
- form_type: 8-K
- ticker: NEO
- cik: 0001077183
- company_name: NEOGENOMICS INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/neo-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001077183-23-000039
- JSON: https://secwatch.observer/filing/0001077183-23-000039.json
- Plain text: https://secwatch.observer/filing/0001077183-23-000039.txt

## Key facts
- Earnings Releases
  NEOGENOMICS INC reported first quarter of 2023 results: revenue $137 million, net income $31 million.
  - Period: first quarter of 2023
  - Revenue: $137 million
  - Net income: $31 million
  - Result: reported results
  source text: First-Quarter Results Consolidated revenue for the first quarter of 2023 was $137 million, an increase of 17% over the same period in 2022. Clinical Services revenue of $115 million was an increase year-over-year of 16%. Clinical test volume (1) increased by 7% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 8% to $402. Pharma Services revenue increased by 22% to $22 million compared to the first quarter of 2022. Consolidated gross profit for the first quarter of 2023 was $54.8 million, an increase of 43.4% compared to the first quarter of 2022. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 39.9%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 43.5%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.